Protalix BioTherapeutics (PLX) Common Equity (2010 - 2026)

Protalix BioTherapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $67.2 million for Q1 2026.

• On a quarterly basis, Common Equity rose 48.71% year-over-year to $67.2 million in Q1 2026; TTM through Mar 2026 was $67.2 million, a 48.71% increase from a year earlier, with the FY2025 full-year figure at $48.2 million, up 11.62% from the prior year.
• Common Equity advanced to $67.2 million in Q1 2026 per PLX's latest filing, from $48.2 million in the prior quarter.
• Across five years, Common Equity topped out at $67.2 million in Q1 2026 and bottomed at -$11.5 million in Q3 2022.
• The 5-year median for Common Equity is $33.6 million (2023), against an average of $27.6 million.
• Across the five-year window, Common Equity tumbled 5505.63% in 2022 and jumped 2854.96% in 2024, its largest moves.
• Year by year, Common Equity stood at -$10.6 million in 2022, then soared by 415.5% to $33.6 million in 2023, then rose by 28.72% to $43.2 million in 2024, then gained by 11.62% to $48.2 million in 2025, then jumped by 39.39% to $67.2 million in 2026.
• Per Business Quant, the three latest PLX Common Equity figures stand at $67.2 million (Q1 2026), $48.2 million (Q4 2025), and $52.9 million (Q3 2025).